目的应用氧化低密度脂蛋白(oxidized low-density lipoprotein,ox-LDL)诱导的小鼠巨噬细胞株制备动脉粥样硬化模型,观察微小RNA-1270(microRNA-1270,miRNA-1270)是否经血管生成素样蛋白7(angiopoietin-like protein 7,ANGPTL7)/p38途径...目的应用氧化低密度脂蛋白(oxidized low-density lipoprotein,ox-LDL)诱导的小鼠巨噬细胞株制备动脉粥样硬化模型,观察微小RNA-1270(microRNA-1270,miRNA-1270)是否经血管生成素样蛋白7(angiopoietin-like protein 7,ANGPTL7)/p38途径干预巨噬细胞炎症及血脂代谢。方法培养小鼠单核巨噬细胞(RAW264.7),并加入ox-LDL构建动脉粥样硬化模型。根据干预条件不同分为空白组、ox-LDL组、ANGPTL7组、p38蛋白抑制组、p65蛋白抑制组、miR-1270模拟物组、miR-1270模拟物阴性对照组、miR-1270抑制物组和miR-1270抑制物阴性对照组。采用实时定量PCR法检测mRNA表达水平,采用Western blotting法检测蛋白质表达水平,采用油红染色法检测脂质蓄积。结果ox-LDL暴露的巨噬细胞中含红色脂肪微粒的巨噬细胞数量增加,ANGPTL7高表达,p38高表达,白介素-6(interleukin-6,IL-6)高表达,白介素-10(interleukin-10,IL-10)低表达,且ANGPTL7与p38及脂质蓄积呈正相关(P<0.01)。与ox-LDL组相比,ANGPTL7组ANGPTL7、p38及IL-6蛋白相对表达量增加,IL-10蛋白相对表达量减少,含红色脂肪微粒的巨噬细胞数量增加(P<0.01)。与ANGPTL7组相比,p38蛋白抑制组ANGPTL7和p38蛋白相对表达量无明显差异,IL-6蛋白相对表达量减少,IL-10蛋白相对表达量增加,含红色脂肪微粒的巨噬细胞数量减少(P<0.01)。与ANGPTL7组相比,p65蛋白抑制组各项指标表达量、含红色脂肪微粒的巨噬细胞数量差异无统计学意义(P>0.05)。与空白组相比,ox-LDL组miR-1270基因相对表达量减少,ANGPTL7基因及蛋白相对表达量增加,miR-1270与ANGPTL7基因相对表达量呈负相关(P<0.01)。与ox-LDL组相比,miR-1270模拟物组miR-1270基因相对表达量增加,ANGPTL7基因及蛋白相对表达量减少,p38及IL-6蛋白相对表达量减少,IL-10蛋白相对表达量增加,含红色脂肪微粒的巨噬细胞数量减少(P<0.01);miR-1270抑制物组miR-1270基因相对表达量减少,ANGPTL7基因及蛋白相对表达量增加,p38及IL-6蛋白相对表达量增加,IL-10蛋白相对表达量减少,含红色脂肪微粒的巨噬细胞数量增加(P<0.01);与ox-LDL组相比,阴性对照物组各项指标表达量无明显差异,含红色脂肪微粒的巨噬细胞数量差异无统计学意义(P>0.05)。结论在ox-LDL暴露的巨噬细胞模型中,ANGPTL7促进巨噬细胞内的炎症和脂质蓄积必经p38途径实现,是促进动脉粥样硬化的发生发展新机制。miR-1270作为保护性因子,可靶向抑制ANGPTL7基因转录表达,经p38途径减轻巨噬细胞炎症及脂质蓄积,可逆调控动脉粥样硬化发生发展,是动脉粥样硬化潜在的早期筛查靶点。展开更多
BACKGROUND Hepatocellular carcinoma(HCC)has been a pervasive malignancy throughout the world with elevated mortality.Efficient therapeutic targets are beneficial to treat and predict the disease.Currently,the exact mo...BACKGROUND Hepatocellular carcinoma(HCC)has been a pervasive malignancy throughout the world with elevated mortality.Efficient therapeutic targets are beneficial to treat and predict the disease.Currently,the exact molecular mechanisms leading to the progression of HCC are still unclear.Research has shown that the microRNA-142-3p level decreases in HCC,whereas bioinformatics analysis of the cancer genome atlas database shows the ASH1L expression increased among liver tumor tissues.In this paper,we will explore the effects and mechanisms of microRNA-142-3p and ASH1L affect the prognosis of HCC patients and HCC cell bioactivity,and the association between them.AIM To investigate the effects and mechanisms of microRNA-142-3p and ASH1L on the HCC cell bioactivity and prognosis of HCC patients.METHODS In this study,we grouped HCC patients according to their immunohistochemistry results of ASH1L with pathological tissues,and retrospectively analyzed the prognosis of HCC patients.Furthermore,explored the roles and mechanisms of microRNA-142-3p and ASH1L by cellular and animal experiments,which involved the following experimental methods:Immunohistochemical staining,western blot,quantitative real-time-polymerase chain reaction,flow cytometric analysis,tumor xenografts in nude mice,etc.The statistical methods involved in this study contained t-test,one-way analysis of variance,theχ^(2)test,the Kaplan-Meier approach and the log-rank test.RESULTS In this study,we found that HCC patients with high expression of ASH1L possess a more recurrence rate as well as a decreased overall survival rate.ASH1L promotes the tumorigenicity of HCC and microRNA-142-3p exhibits reduced expression in HCC tissues and interacts with ASH1L through targeting the ASH1L 3′untranslated region.Furthermore,microRNA-142-3p promotes apoptosis and inhibits proliferation,invasion,and migration of HCC cell lines in vitro via ASH1L.For the exploration mechanism,we found ASH1L may promote an immunosuppressive microenvironment in HCC and ASH1L affects the expression of the cell junction protein zonula occludens-1,which is potentially relevant to the immune system.CONCLUSION Loss function of microRNA-142-3p induces cancer progression and immune evasion through upregulation of ASH1L in HCC.Both microRNA-142-3p and ASH1L can feature as new biomarker for HCC in the future.展开更多
基金Supported by the Haihe Laboratory of Cell Ecosystem Innovation Fund,No.22HHXBJC00001the Key Discipline Special Project of Tianjin Municipal Health Commission,No.TJWJ2022XK016.
文摘BACKGROUND Hepatocellular carcinoma(HCC)has been a pervasive malignancy throughout the world with elevated mortality.Efficient therapeutic targets are beneficial to treat and predict the disease.Currently,the exact molecular mechanisms leading to the progression of HCC are still unclear.Research has shown that the microRNA-142-3p level decreases in HCC,whereas bioinformatics analysis of the cancer genome atlas database shows the ASH1L expression increased among liver tumor tissues.In this paper,we will explore the effects and mechanisms of microRNA-142-3p and ASH1L affect the prognosis of HCC patients and HCC cell bioactivity,and the association between them.AIM To investigate the effects and mechanisms of microRNA-142-3p and ASH1L on the HCC cell bioactivity and prognosis of HCC patients.METHODS In this study,we grouped HCC patients according to their immunohistochemistry results of ASH1L with pathological tissues,and retrospectively analyzed the prognosis of HCC patients.Furthermore,explored the roles and mechanisms of microRNA-142-3p and ASH1L by cellular and animal experiments,which involved the following experimental methods:Immunohistochemical staining,western blot,quantitative real-time-polymerase chain reaction,flow cytometric analysis,tumor xenografts in nude mice,etc.The statistical methods involved in this study contained t-test,one-way analysis of variance,theχ^(2)test,the Kaplan-Meier approach and the log-rank test.RESULTS In this study,we found that HCC patients with high expression of ASH1L possess a more recurrence rate as well as a decreased overall survival rate.ASH1L promotes the tumorigenicity of HCC and microRNA-142-3p exhibits reduced expression in HCC tissues and interacts with ASH1L through targeting the ASH1L 3′untranslated region.Furthermore,microRNA-142-3p promotes apoptosis and inhibits proliferation,invasion,and migration of HCC cell lines in vitro via ASH1L.For the exploration mechanism,we found ASH1L may promote an immunosuppressive microenvironment in HCC and ASH1L affects the expression of the cell junction protein zonula occludens-1,which is potentially relevant to the immune system.CONCLUSION Loss function of microRNA-142-3p induces cancer progression and immune evasion through upregulation of ASH1L in HCC.Both microRNA-142-3p and ASH1L can feature as new biomarker for HCC in the future.
